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Immunogenicity and safety of an adjuvanted hepatitis B vaccine
in pre-hemodialysis and hemodialysis patients.
Background. Due to their impaired immune system, pa-
tients with renal insufficiency have a suboptimal response to
hepatitis B (HB) vaccination and frequent boosters are needed
to maintain protection. GlaxoSmithKline Biologicals has devel-
oped a HB vaccine containing a new adjuvant system AS04 for
use in this immunocompromised patient population.
Methods. In an open, randomized clinical trial con-
ducted in pre-hemodialysis (documented creatinine clearance
≤30 mL/min) and hemodialysis patients, over 15 years of age
and naı¨ve for HB, the immunogenicity and safety of single doses
of HB-AS04 (FendrixTM, GlaxoSmithKline Biologicals) were
compared to double doses of commercially available HB vac-
cine (EngerixTM, GlaxoSmithKline Biologicals) administered
at 0, 1, 2, and 6 months, and followed-up for 36 months.
Results. The HB-AS04 vaccine elicited a more rapid onset
of protection than the currently licensed vaccine for this par-
ticular population, with 74% versus 52% of subjects seropro-
tected at month 3. After the vaccination course, seroprotection
rates increased to 91% versus 84% in the HB-AS04 and stan-
dard vaccine groups, respectively. Differences persisted up to
36 months post-vaccination (73% vs. 52%, respectively). Anti-
body concentrations were higher following the HB-AS04 vac-
cine at all post-vaccination time points. During the follow-up,
significantly fewer subjects primed with the HB-AS04 vaccine
needed a booster dose as a consequence of anti-HBs loss be-
low seroprotective levels (11/62 subjects in the HB-AS04 group
vs. 22/57 subjects in the standard vaccine group, respectively,
P = 0.014). The HB-AS04 was more locally reactogenic than
the standard immunization regimen, with pain at the injection
site occurring with 41% of HB-AS04 doses versus 19% of stan-
dard vaccine doses. The occurrence of grade 3 pain was less
than 1% in both groups and all events resolved within the 4-day
follow-up period.
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Conclusion. The improved immunogenicity profile and clin-
ically acceptable reactogenicity of HB-AS04 vaccine are of key
importance to provide a more rapid, enhanced, and longer sero-
protection to these immunocompromised patients at risk for
HB infection.
Currently available hepatitis B (HB) vaccines have
an excellent safety and immunogenicity profile, con-
ferring seroprotection in more than 95% of the vacci-
nated population [1]. Nevertheless, certain population
subgroups, such as some healthy people and immuno-
compromised subjects, do not respond adequately to
vaccination. Among these groups, end-stage renal dis-
ease (ESRD) patients, comprising pre- and hemodialy-
sis patients, are considered at high risk for HB infection
due to cross-contamination to patients via environmen-
tal surfaces, disposables, or equipment during the pro-
cess of hemodialysis [2–5]. Once infected, about 60% of
hemodialysis patients will become chronic carriers of the
HB surface antigen (HBsAg), increasing the risk of con-
tamination for other hemodialysis patients, medical per-
sonnel, and family members [6], and leading to significant
logistic and practical difficulties, including provision for
separate medical devices and staff.
Attempts to overcome the impaired immune response
in hemodialysis patients have produced mixed results. An
increased dose strategy with additional injections was
found to be necessary to improve the response rate in
these subjects. Currently a 0-, 1-, 2-, and 6-month schedule
with double doses hepatitis B surface antigen (2 × 20 lg
HBsAg) of commercially available HB vaccine is recom-
mended in hemodialysis patients, with regular monitoring
of antibody levels to ensure that antibody concentrations
remain above the protective level of 10 mIU/mL [7].
In order to improve the immunogenicity of existing
HB vaccines, GlaxoSmithKline Biologicals (Rixensart,
Belgium) has developed several adjuvant systems
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containing immunostimulants. One of them was shown to
significantly increase the immune response to the HBsAg
and has been used in the formulation of an improved HB
vaccine. The new adjuvant system, AS04, is composed
of aluminium salt and 3-O-desacyl-4′-monophosphoryl
lipid A (MPL, Corixa, Seattle, WA, USA). In the case
of pre-hemodialysis and hemodialysis patients, the im-
paired immune response observed in this group, includ-
ing a diminished activation of helper T-cells, can in part
be explained by a suboptimal costimulation by antigen
presenting-cells due to a deficit of CD86. The hypothe-
sis, therefore, is that, in these patients, the adjuvant sys-
tem AS04 could stimulate cellular and humoral responses
via an increased antigen-presenting capacity through up-
regulation of the CD86 molecule and/or via an increased
production of cytokines.
Several studies in which 3500 subjects received 8670
doses of different formulations of the candidate vaccine
were performed and have shown that the HB-AS04 vac-
cine is safe and immunogenic in different populations
[8–11].
To further characterize the immune response induced
by the HB-AS04 vaccine, cell-mediated immunity (CMI)
data were collected as exploratory measurements in sev-
eral studies performed in healthy subjects. These data in-
cluded measurement of lymphoproliferation (expressed
as stimulation index) and lymphokines (IFNc and IL-5)
secretion in subgroups of subjects enrolled in these stud-
ies. The results indicated that when similar schedules were
compared, the HB-AS04 vaccine tended to improve the
cellular response and to increase IFNc secretion, sug-
gesting that part of the immune response follows a Th-1
pathway.
In this open, randomized clinical trial conducted in pre-
hemodialysis and hemodialysis patients over 15 years of
age, the immunogenicity and safety of HB-AS04 were
compared to the currently recommended immunization
regimen for these patients.
METHODS
Study population and design
In 1999, 165 ESRD patients were enrolled into this
multinational study conducted at 6 study centers in Spain,
Czech Republic, and Malaysia, respectively. The study
was approved by the respective institutional ethics review
boards, and was conducted according to the Declaration
of Helsinki and Good Clinical Practice guidelines effec-
tive at study initiation. Written informed consent in the
local language was obtained from the subjects or parents
or guardians prior to entry into the trial.
Subjects were excluded if they had hepatomegaly,
elevated serum liver enzymes, history of allergic dis-
ease likely to be stimulated by any vaccine com-
ponent, a family history of congenital or hereditary
immunodeficiency, received simultaneous vaccination
or immunoglobulins and/or any blood products (with
the exception of recombinant erythropoietin), or were
receiving immunosuppressive therapy. Eligible pre-
hemodialysis and hemodialysis (documented creatinine
clearance ≤30 mL/min) subjects over 15 years of age and
naive for HB were randomized to 1 of 2 groups to receive
either single doses of HB-AS04 vaccine or the current
standard of care [i.e., double doses (2 × 20 lg HBsAg)
of commercial HB vaccine at 0, 1, 2, and 6 months] and
followed-up for 36 months.
Materials. Both vaccines are commercially avail-
able and manufactured by GlaxoSmithKline Biologicals,
Rixensart, Belgium. One dose (0.5 mL) of HB-AS04
(FendrixTM) contained 20 lg of recombinant HBsAg,
50 lg of MPL, and 0.5 mg of aluminium as salt. One dose
(1.0 mL) of the commercial HB vaccine (EngerixTM-B)
was composed of 20 lg recombinant HBsAg and 0.5 mg
aluminium as salt; two 1.0 mL monodose vials of the vac-
cine were mixed and given as a single injection. In ac-
cordance with current standard of care for hemodialysis
patients, both vaccines were administered at 0, 1, 2, and
6 months as an intramuscular injection in the deltoid re-
gion of the arm without the hemodialysis arteriovenous
fistula.
Methods. Prevaccination blood samples obtained at
screening and postvaccination blood samples obtained at
months 1, 2, 3, 6, 7, and at months 12, 24, 30, 36 for persis-
tence data, were assayed for the presence of antibodies
against HBsAg (anti-HBs) using a commercial enzyme-
immunoassay (EIA) produced by Abbott Laboratories
(AUSAB, Abbott Laboratories, Abbott Park, IL, USA).
The assay cut-off was 3.3 mIU/mL; antibody concentra-
tions ≥ this cut-off were designated as seropositive. Sero-
protection was defined as anti-HBs concentration ≥10
mIU/mL.
Local injection site symptoms (pain, redness, swelling)
and general symptoms (headache, fatigue, gastrointesti-
nal symptoms, fever) were solicited on the day of vac-
cination and for 3 subsequent days. The size of redness
and swelling was obtained by measuring the largest di-
ameter; a grade 3 event was defined as a diameter over
50 mm. Grade 3 injection site pain was defined as “spon-
taneously painful.” Subjects were asked to record axil-
lary temperature daily and any other findings on diary
cards and to contact the investigator immediately if they
felt any symptom was serious. Fever was defined as axil-
lary temperature above 37.4◦C; grade 3 fever was axillary
temperature above 39◦C. Any signs and symptoms that
prevented normal daily activities were designated grade 3
in intensity. Serious adverse events, defined according to
Good Clinical Practice guidelines, that occurred at any
time throughout the study period up to at least 30 days
after receiving the last vaccine dose were reported and
described in detail.
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Statistical methods
In accordance with sample size calculations performed
for the primary study, assuming that the seroprotection
rate would be equal to 71% in the EngerixTM-B group and
91% in the HB-AS04 group, 57 evaluable subjects in each
group were needed to reject the null hypothesis that HB-
AS04 vaccine was not better than EngerixTM-B with at
least 80% power, using a one-sided (a = 5%) Fisher exact
test. Allowing for 20% of subjects not to be evaluable
for analysis, 72 subjects per treatment group (a total of
144 subjects) were planned to be enrolled, and an over-
randomization was prepared for 196 subjects. However,
for the analysis, it was decided to apply two-sided test
calculations.
For each blood sampling time point, the percent-
age of subjects with anti-HBs concentrations ≥10 and
≥100 mIU/mL, and geometric mean concentrations
(GMC) of anti-HBs were calculated with 95% CI. Anti-
HBs seroprotection rates were compared between groups
using two-sided Fisher exact test. Wilcoxon’s test was
used to compare GMCs, which were calculated using log
transformation of positive concentrations and taking the
antilog of the mean of the transformed values. A P value
< 0.05 was considered statistically significant. The per-
centage of doses followed by any solicited/unsolicited
symptoms was calculated with exact 95% CI following
each vaccination and overall.
RESULTS
The demographic profile of the 2 study groups was sim-
ilar in terms of mean age, body mass index, male:female
ratio, and smoking habit (Table 1). The mean hemodial-
ysis duration was longer in the comparator group
(22.5 months) than in the HB-AS04 group (15.1 months)
due to the influence on the mean by a very long hemodial-
ysis period in 2 subjects (132 months and 239 months).
Without these 2 outliers, the mean hemodialysis duration
of the comparator group becomes 14.1 months, similar to
that of the HB-AS04 group.
Immunogenicity of the vaccine
As can be seen in Table 2, a significantly faster on-
set of protection (antibody concentration ≥10 mIU/mL)
was observed in the HB-AS04 group from month 1 to
month 6. At month 3, essentially three fourths (74.4%)
of the subjects in the HB-AS04 group were seropro-
tected against HB as compared to one half (52.4%) of
subjects in the comparator group. Despite a statistically
significant difference between the groups at earlier time
points and an observed increase in the seroprotection rate
at month 7 (HB-AS04: 90.9% vs. comparator: 84.4%),
a statistically significant difference was not seen at
Table 1. Demographic characteristics (total cohort)
FendrixTM EngerixTM-B
(N = 82) (N = 83)
Age years 58.7 ± 15.50a 58.6 ± 15.46a
Body mass index 25.0 ± 5.04a 25.0 ± 4.78a
Male:female 1:0.78 1:0.73
Smoking habit 4.9% 8.4%b
Pre-hemodialysis 46% 51%
Hemodialysis 54% 49%
Months on hemodialysis 15.1 ± 17.5a,c 22.5 ± 42.1a
Frequency of hemodialysis times/week 2.9 ± 0.46a 2.8 ± 0.50a
aMean ± standard deviation.
bP = 0.5346, 2-sided Fisher exact test.
cThere was no significant difference between study groups after exclusion of
2 subjects with very long hemodialysis periods.
month 7. The percentage of subjects with antibody con-
centrations ≥100 mIU/mL was greater at all time points
in the HB-AS04 group, which was statistically significant
from month 3 to month 7. Significantly higher GMCs
(P ≤ 0.05) were obtained in the HB-AS04 group than
the comparator group at all time points from month 3
to month 7. At month 7, GMCs were more than three-
fold higher in the HB-AS04 group than in the comparator
group (3559 mIU/mL vs. 933 mIU/mL).
As shown in Table 3, the persistence of protective an-
tibody levels was higher in the HB-AS04 group than in
the comparator group at all time points (months 12, 24,
30, 36). The difference in seroprotection rates between
groups was statistically significant at month 36 (P = 0.03).
At month 36, a seroprotection rate of 72.9% was still
observed in the HB-AS04 group versus 52.0% in the
comparator group. A higher percentage of subjects also
retained anti-HBs concentrations above 100 mIU/mL in
the HB-AS04 group (54.2%) versus comparator group
(36.0%).
Anti-HBs GMCs in HB-AS04 recipients were higher
than in subjects administered comparator at month 36
(173.4 mIU/mL vs. 99.6 mIU/mL). However, the differ-
ence between groups was not statistically significant.
During the follow-up, significantly fewer subjects
primed with the HB-AS04 vaccine needed a booster
dose as a consequence of anti-HBs loss below seropro-
tective levels (11/62 subjects in the HB-AS04 group vs.
22/57 subjects in the standard vaccine group, respectively,
P = 0.014).
Safety and reactogenicity of the vaccine
The overall incidence of local symptoms (solicited or
unsolicited) was higher in the HB-AS04 group than that
observed in the comparator group (Table 4), resulting
from the higher incidence of pain at the injection site
(40.5% vs. 14.7% of doses in the HB-AS04 and com-
parator groups, respectively). However the incidence of
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Table 2. Seroprotection rates (SP) and GMCs for anti-HBs antibodies (total cohort)
FendrixTM (N = 82) EngerixTM-B (N = 83)
Timing % 95% CI % 95% CI P value
SP concentration ≥10 mIU/mL PI(M1) 17.5 9.9; 27.6 4.8 1.3; 11.9 0.0120
PII(M2) 48.7 37.2; 60.3 21.7 13.4; 32.1 <0.001
PIII(M3) 74.4 63.2; 83.6 52.4 41.1; 63.6 0.0053
PIII(M6) 81.8 71.4; 89.7 66.2 54.6; 76.6 0.0425
PIV(M7) 90.9 82.2; 96.3 84.4 74.4; 91.7 NS
SP concentration ≥100 mIU/mL PI(M1) 5.0 1.4; 12.3 2.4 0.3; 8.4 NS
PII(M2) 16.7 9.2; 26.8 7.2 2.7; 15.1 NS
PIII(M3) 41.0 30.0; 52.7 15.9 8.7; 25.6 <0.001
PIII(M6) 61.0 49.2; 72.0 35.1 24.5; 46.8 0.0021
PIV(M7) 83.1 72.9; 90.7 67.5 55.9; 77.8 0.0389
GMC mIU/mL PI(M1) 36.1 13.7; 95.0 28.7 4.0; 206.1 NS
PII(M2) 74.5 41.8; 132.8 55.8 25.1; 124.1 NS
PIII(M3) 223.0 129.3; 384.6 50.1 30.8; 81.5 <0.001
PIII(M6) 247.9 154.1; 398.9 89.5 57.0; 140.6 0.0028
PIV(M7) 3559.2 2130.3; 5946.5 933.0 515.8; 1687.8 0.0005
Abbreviations are : SP, seroprotection rate; NS: not significant; PI(M1), etc., postdose 1 (month 1), etc.; 95% CI, lower and upper limits of 95% CI.
Table 3. Persistence data for seroprotection rates (SP) and GMCs for anti-HBs antibodies (total cohort)
FendrixTM EngerixTM-B
Timing N % 95% CI N % 95% CI P value
SP concentration ≥10 mIU/mL PIV(M7) 77 90.9 82.2; 96.3 77 84.4 74.4; 91.7 NS
PIV(M12) 71 85.9 75.6; 93.0 70 77.1 65.6; 86.3 NS
PIV(M24) 62 80.6 68.6; 89.6 57 70.2 56.6; 81.6 NS
PIV(M30) 60 76.7 64.0; 86.6 53 60.4 46.0; 73.5 NS
PIV(M36) 59 72.9 59.7; 83.6 50 52.0 37.4; 66.3 0.0293
SP concentration ≥100 mIU/mL PIV(M7) 77 83.1 72.9; 90.7 77 67.5 55.9; 77.8 0.0389
PIV(M12) 71 73.2 61.4; 83.1 70 54.3 41.9; 66.3 0.0231
PIV(M24) 62 61.3 48.1; 73.4 57 47.4 34.0; 61.0 NS
PIV(M30) 60 58.3 44.9; 70.9 53 37.7 24.8; 52.1 0.0381
PIV(M36) 59 54.2 40.8; 67.3 50 36.0 22.9; 50.8 NS
GMC mIU/mL PIV(M7) 77 3559.2 2130.3; 5946.5 77 933.0 515.8; 1687.8 0.0005
PIV(M12) 71 907.6 579.1; 1422.3 70 320.8 186.4; 552.2 0.0037
PIV(M24) 62 334.3 202.1; 553.0 57 253.8 137.4; 468.9 NS
PIV(M30) 60 205.7 122.3; 345.9 53 111.9 57.4; 218.1 NS
PIV(M36) 59 173.4 100.1; 300.6 50 99.6 49.5; 200.4 NS
Abbreviations are: SP, seroprotection rate; NS: not significant; PIV(M7), etc., postdose 4 (month 7), etc.; 95% CI, lower and upper limits of 95% CI.
grade 3 pain remained low and comparable in the 2 groups
(0.6% in both groups). There was no increase in the inci-
dence of pain with subsequent doses, and all pain symp-
toms resolved during the 4-day follow-up period.
For the 4 solicited general symptoms, a similar inci-
dence was observed in the 2 groups, with fatigue reported
most frequently (Table 4). Few solicited general symp-
toms were scored as grade 3 (i.e., 3.2% vs. 1.5% of doses
in the HB-AS04 and comparator groups, respectively).
Over the active phase of the study, 63 unsolicited
symptoms were reported in the HB-AS04 group and 44
unsolicited symptoms in the comparator group. Unso-
licited symptoms of grade 3 intensity were reported after
19 doses of HB-AS04 and 18 doses of comparator. Three
unsolicited symptoms were considered to have a ‘prob-
able/suspected’ relationship to study medication in the
HB-AS04 group compared to 7 in the comparator group;
none of these events were of intensity grade 3.
A total of 39 serious adverse events were reported dur-
ing the active phase of the study (21 in the HB-AS04
group and 18 in the comparator group), 6 of which were
fatal events (2 vs. 4 in the HB-AS04 and comparator
groups, respectively). All of these events were deter-
mined by the investigator to be unrelated to vaccination.
DISCUSSION
Due to their impaired immune system, patients with
renal insufficiency have a suboptimal response to hepati-
tis B (HB) vaccination, and frequent boosters are needed
to maintain protection [12–16]. In the target population
of pre-hemodialysis and hemodialysis patients, the HB-
AS04 vaccine induced a more rapid onset of protection
than the comparator vaccine, which has a licensed sched-
ule for this particular population. Indeed, 3 months after
the first vaccine dose, 74.4% of the HB-AS04 recipients
were seroprotected, compared to 52.4% of the compara-
tor recipients. Fast onset of protection is of particular
importance for this population at increased risk for HB
infection. As previously mentioned, the risk to contract
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Table 4. Percentage of doses leading to reported symptom (total cohort)
FendrixTM (N = 317) EngerixTM-B (N = 327)
N % 95% CI N % 95% CI
Any symptom Total 168 53.0 47.3; 58.6 132 40.4 35.0; 45.9
(solicited/unsolicited) Grade 3 13 4.1 2.2; 6.9 6 1.8 0.7; 4.0
Solicited injection site symptoms
Pain Total 128 40.5 35.0; 46.1 48 14.7 11.0; 19.0
Grade 3a 2 0.6 0.1; 2.3 2 0.6 0.1; 2.2
Redness Total 23 7.3 4.7; 10.7 22 6.7 4.3; 10.0
Grade 3a 0 0.0 0.0; 1.2 0 0.0 0.0; 1.1
Swelling Total 20 6.3 3.9; 9.6 12 3.7 1.9; 6.3
Grade 3a 2 0.6 0.1; 2.3 0 0.0 0.0; 1.1
Solicited general symptoms
Fatigue Total 50 15.8 12.0; 20.3 57 17.4 13.5; 22.0
Grade 3b 6 1.9 0.7; 4.1 3 0.9 0.2; 2.7
Gastrointestinal Total 14 4.4 2.4; 7.3 22 6.7 4.3; 10.0
symptoms Grade 3b 0 0.0 0.0; 1.2 0 0.0 0.0; 1.1
Headache Total 37 11.7 8.4; 15.8 45 13.8 10.2; 18.0
Grade 3b 2 0.6 0.1; 2.3 1 0.3 0.0; 1.7
Fever Total 30 9.5 6.5; 13.3 32 9.8 6.8; 13.5
Grade 3b 0 0.0 0.0; 1.2 0 0.0 0.0; 1.1
N, total number of documented doses; N and%, number and percentage of doses followed by specified symptom; 95% CI, lower and upper limits of 95% CI.
aSpontaneously painful or greatest surface diameter of redness/swelling >50 mm
bPrevented normal daily activities or axillary temperature >39◦C
HB infection exists for these patients from the start of
hemodialysis treatment due to potentially contaminated
blood products or medical devices. Moreover, for patients
who will undergo renal transplantation, protection before
transplantation is important in order to avoid de novo HB
acquired during or after transplantation and non- or poor
responsiveness to vaccination linked to immunosuppres-
sive drugs.
Although statistical comparison failed to show supe-
riority of the HB-AS04 vaccine in terms of seroprotec-
tion (anti-HBs antibody concentrations ≥10 mIU/mL) at
month 7, it is important to note that the seroprotection
rate observed in the HB-AS04 group at this time point
was 90.9%, which is higher than expected in this popula-
tion of immune-deficient patients.
In the normal healthy population, long-term protection
relies on immune memory in subjects reaching anti-HBs
concentrations ≥10 mIU/mL postvaccination. However,
in immunocompromised subjects, protection against hep-
atitis B infection does not rely on immune memory, but on
circulating antibodies. Prospective studies in hemodialy-
sis patients have shown that many individuals with anti-
HBs levels between 10 and 100 mIU/mL do not retain
protective antibody levels 1 year postvaccination. It has
been suggested that an acceptable response to hepatitis B
vaccination in hemodialysis patients corresponds to anti-
HBs concentrations ≥100 mIU/mL, allowing protection
to last for 1 year postvaccination [17, 18]. According to
European vaccination advisory bodies [19, 20], a cut-off
at 100 mIU/mL is considered to be necessary for main-
taining protection in immunocompromised patients. The
percentage of subjects with anti-HBs antibody concentra-
tions ≥100 mIU/mL was significantly higher in the HB-
AS04 group than in the comparator group at all time
points from month 3 to month 12.
Based on the higher GMCs after vaccination, a longer
persistence of circulating anti-HBs antibodies would be
expected with HB-AS04 as compared with the current
standard of care. While the actual rate of antibody decline
is independent of the initial post-vaccination antibody
concentration, vaccinees with higher concentrations have
been shown to retain antibody for a longer period of time
[21]. Indeed, the data on the persistence of HB-AS04 at
month 36 confirm the hypothesis that, by inducing higher
anti-HBs concentrations, a better persistence of seropro-
tection is reached after vaccination of hemodialysis pa-
tients with HB-AS04.
As a consequence of better persistence of anti-HBs
antibodies observed in the HB-AS04 group, and impor-
tantly from a medical point of view, fewer subjects in this
group required booster doses, as compared to subjects in
the standard vaccine group.
The reactogenicity profile of HB-AS04 in a total of 82
pre-hemodialysis and hemodialysis patients was gener-
ally comparable to that seen in healthy subjects [11]. The
overall reactogenicity of the HB-AS04 vaccine was higher
than the comparator vaccine due to an increase in lo-
cal reactogenicity. On the contrary, incidences of general
symptoms (any grade) were similar in the 2 groups and
grade 3 general symptoms remained infrequent (≤3% of
doses). The higher local reactogenicity was mainly due
to a higher incidence of pain (40.5% with HB-AS04 vs.
14.7% with the comparator). However, occurrence of
grade 3 pain was very low and similar in both groups. As
a consequence, the higher incidence of mild or moderate
transient local symptoms remained clinically acceptable
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and was compensated by an improved immunogenicity,
which is of key importance for these immunocompro-
mised patients who are at high risk for HB infection.
CONCLUSION
The improved immunogenicity profile and acceptable
reactogenicity of HB-AS04 vaccine are key factors to pro-
viding a more rapid, enhanced, and longer seroprotection
to immunocompromised hemodialysis patients at risk for
HB infection.
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